The global market for Psoriatic Arthritis Therapeutics was valued at US$11.6 Billion in 2024 and is projected to reach US$20.5 Billion by 2030, growing at a CAGR of 10% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
In recent years, significant advancements in the understanding of PsA's pathophysiology have led to the development of biologic therapies, which target specific components of the immune system that drive the disease. Tumor necrosis factor (TNF) inhibitors, such as adalimumab and etanercept, were among the first biologics approved for PsA treatment and have shown substantial efficacy in reducing joint and skin symptoms. More recently, interleukin (IL) inhibitors that target IL-17 and IL-23, such as secukinumab and ustekinumab, have been introduced, offering alternative mechanisms of action for patients who do not respond to TNF inhibitors. Additionally, small molecule inhibitors like Janus kinase (JAK) inhibitors and phosphodiesterase 4 (PDE4) inhibitors provide oral therapeutic options that are effective in controlling PsA symptoms. These therapies have transformed the treatment landscape of PsA, providing more personalized and effective options for patients.
The growth in the psoriatic arthritis therapeutics market is driven by several factors, including the increasing prevalence of the disease and a heightened awareness and diagnosis rate among healthcare professionals. Advancements in biotechnology and pharmaceutical research have led to the development of new and more effective treatments, expanding the range of therapeutic options available. The rising demand for biologics and targeted therapies, driven by their efficacy and relatively favorable side effect profiles, significantly contributes to market growth. Moreover, patient behavior is shifting towards seeking more advanced and specialized treatments, supported by greater access to healthcare information and improved healthcare infrastructure globally. Economic factors, such as increased healthcare expenditure and insurance coverage for chronic diseases, further support market expansion. Additionally, ongoing clinical trials and research into novel therapeutic targets promise to introduce new and improved treatments, ensuring sustained growth and innovation in the psoriatic arthritis therapeutics market. These factors collectively foster an environment where continuous advancements are made, aiming to enhance patient outcomes and quality of life for those suffering from PsA.
Global Psoriatic Arthritis Therapeutics Market - Key Trends and Drivers Summarized
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects both the skin and joints, intertwining the symptoms of psoriasis with those of arthritis. This autoimmune disorder manifests in various forms, ranging from mild to severe, with symptoms including joint pain, stiffness, and swelling, along with the characteristic red, scaly patches of psoriasis. The management of PsA requires a comprehensive therapeutic approach that addresses both skin and joint symptoms to prevent joint damage and improve quality of life. The primary goal of PsA therapeutics is to reduce inflammation, control symptoms, and inhibit disease progression. Treatment regimens often begin with non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids to manage pain and inflammation, moving on to disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, when initial treatments are insufficient.In recent years, significant advancements in the understanding of PsA's pathophysiology have led to the development of biologic therapies, which target specific components of the immune system that drive the disease. Tumor necrosis factor (TNF) inhibitors, such as adalimumab and etanercept, were among the first biologics approved for PsA treatment and have shown substantial efficacy in reducing joint and skin symptoms. More recently, interleukin (IL) inhibitors that target IL-17 and IL-23, such as secukinumab and ustekinumab, have been introduced, offering alternative mechanisms of action for patients who do not respond to TNF inhibitors. Additionally, small molecule inhibitors like Janus kinase (JAK) inhibitors and phosphodiesterase 4 (PDE4) inhibitors provide oral therapeutic options that are effective in controlling PsA symptoms. These therapies have transformed the treatment landscape of PsA, providing more personalized and effective options for patients.
The growth in the psoriatic arthritis therapeutics market is driven by several factors, including the increasing prevalence of the disease and a heightened awareness and diagnosis rate among healthcare professionals. Advancements in biotechnology and pharmaceutical research have led to the development of new and more effective treatments, expanding the range of therapeutic options available. The rising demand for biologics and targeted therapies, driven by their efficacy and relatively favorable side effect profiles, significantly contributes to market growth. Moreover, patient behavior is shifting towards seeking more advanced and specialized treatments, supported by greater access to healthcare information and improved healthcare infrastructure globally. Economic factors, such as increased healthcare expenditure and insurance coverage for chronic diseases, further support market expansion. Additionally, ongoing clinical trials and research into novel therapeutic targets promise to introduce new and improved treatments, ensuring sustained growth and innovation in the psoriatic arthritis therapeutics market. These factors collectively foster an environment where continuous advancements are made, aiming to enhance patient outcomes and quality of life for those suffering from PsA.
Report Scope
The report analyzes the Psoriatic Arthritis Therapeutics market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments
Drug Class (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel).Geographic Regions/Countries
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) segment, which is expected to reach US$6.6 Billion by 2030 with a CAGR of a 9.3%. The Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) segment is also set to grow at 9.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $3.1 Billion in 2024, and China, forecasted to grow at an impressive 16.7% CAGR to reach $5.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AbbVie Inc, Aclaris Therapeutics, Inc., Amgen, Inc., Bristol-Myers Squibb Co, Coherus BioSciences, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Psoriatic Arthritis Therapeutics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Psoriatic Arthritis Therapeutics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Psoriatic Arthritis Therapeutics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 36 major companies featured in this Psoriatic Arthritis Therapeutics market report include:
- AbbVie Inc
- Aclaris Therapeutics, Inc.
- Amgen, Inc.
- Bristol-Myers Squibb Co
- Coherus BioSciences, Inc.
- Eli Lilly and Company
- Fresenius Kabi USA
- GSK Plc
- Johnson & Johnson Services, Inc.
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- SANOFI
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- UCB S.A.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Aclaris Therapeutics, Inc.
- Amgen, Inc.
- Bristol-Myers Squibb Co
- Coherus BioSciences, Inc.
- Eli Lilly and Company
- Fresenius Kabi USA
- GSK Plc
- Johnson & Johnson Services, Inc.
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- SANOFI
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- UCB S.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 276 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 11.6 Billion |
| Forecasted Market Value ( USD | $ 20.5 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
